Business Wire·Apr 22, 2026, 8:00 PM ET

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

Investors who lost money on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) can contact Lauren Molinaro of Kirby McInerney LLP at investigations@kmllp.com to discuss rights in a securities fraud class action at no cost.
The deadline for investors to request appointment as lead plaintiff is May 29, 2026, as courts will not consider late applications.
The lawsuit covers the class period from November 3, 2023, through March 16, 2026, alleging Aldeyra failed to disclose inconsistent reproxalap clinical trial results.
The complaint asserts that the inconsistency of trial data rendered positive findings unreliable and meaningless.
On March 17, 2026, Aldeyra filed an SEC Form 8-K announcing an FDA Complete Response Letter stating the drug lacked substantial evidence of efficacy for dry eye disease.
The FDA letter cited inconsistent study results as raising serious concerns regarding the reliability of positive findings.
Following the March 17, 2026 announcement, Aldeyra shares fell $2.99 per share, or 71%, from $4.23 to close at $1.24.
Kirby McInerney LLP is a New York-based plaintiffs' firm specializing in securities litigation with billions in past recoveries.